Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Hussain, Maha; Tombal, Bertrand; Saad, Fred; Fizazi, Karim; N. Sternberg, Cora; David Crawford, E.; D. Shore, Neal; Kopyltsov, Evgeny; Rezazadeh Kalebasty, Arash; Bögemann, Martin; Ye, Dingwei; José Silva Melo Cruz, Felipe; Suzuki, Hiroyoshi; Kapur, Shivani; Srinivasan, Shankar; Verholen, Frank; Kuss, Iris; Joensuu, Heikki; R. Smith, Matthew

doi:10.1200/jco.23.00041

Public

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Published in Journal of Clinical Oncology • Feb 16, 2023

Authors:

Maha Hussain

Bertrand Tombal

Fred Saad

Abstract

PURPOSE: For patients with metastatic hormone-sensitive prostate cancer, metastatic burden affects outcome. We examined efficacy and safety from the ARASENS trial for subgroups by disease volume and risk. METHODS: Patients with metastatic hormone-sensitive prostate cancer were randomly assigned to d...

Subject

Medicine

Prostate cancer

Docetaxel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!